類風濕性關節炎治療劑农业专利-农业学术服务平台

发明人:: IGAWA, TOMOYUKI,井川智之,ISHII, SHINYA,石井慎也,MAEDA, ATSUHIKO,前田敦彦,前田敦彥,SAKURAI, MIKA,樱井实香,櫻井實香,KOJIMA, TETSUO,小嶋哲郎,TACHIBANA, TATSUHIKO,橘达彦,橘達彥,SHIRAIWA, HIROTAKE,白岩宙丈,TSUNODA, HIROYUKI

摘要：: By properly combining complementarity determining region (CDR) amino acid sequence modification, variable region amino acid sequence modification, and constant region amino acid sequence modification, a treatment agent for rheumatoid arthritis, juvenile chronic arthritis, and Castleman's disease was successfully created which has, as an active ingredient, an IL-6 receptor antibody which has improved material properties, safety, immunogenicity, pharmacokinetics (retentivity in blood plasma), and antigen neutralization which are superior to tocilizumab.本發明以適當地組合CDR區域胺基酸序列的改變、可變區域胺基酸序列的改變、恆定區域胺基酸序列的改變，成功地創製以較托珠單抗(TOCILIZUMAVB，為第6介質素受體抗體)更為優異之抗原中和能力、藥物動態(血中滯留性)、免疫原性、安全性、物性均改良之抗IL-6受體抗體作為有效成份之類風濕性關節炎、兒童慢性關節炎或卡斯托曼病之治療劑。